Abstract

Background. Bloodstream infections (BSI) are common after allogeneic hematopoietic stem cell transplantation (allo-HSCT). The objective of study was to analyze pre- and post-engraftment BSI.Materials and methods. From January 2018 till May 2021242 patients after first allo-HSCT were enrolled in the study. Median age was 35 (17–65) years. The majority of transplants were done for acute leukemias (71.9 %) in remission (91.7 %) with reduced-intensity conditioning regimens (71.5 %) and peripheral blood stem cells (74.4 %) as a graft source.Results. Of 242 patients 95 (39.2 %) developed BSI: 79 (83.2 %) developed 1 BSI episode, 16 (16.8 %) – 2 or more. Overall 113 BSI episodes were registered: 94 (82.7 %) were caused by single microorganism, 19 (17.3 %) were polymicrobial. Probability of pre-engraftment BSI was 31.0 %, post-engraftment – 11.8 %. In total 134 microorganisms were identified: 61.2 % – gram-negative and 38.8 % – gram-positive bacteria. Gram-negative BSI rate was significantly higher during post-engraftment compared to pre-engraftment phase (57.7 % vs. 70.3 %; р = 0.008). Major risk factor for pre-engraftment BSI was mismatched unrelated allo-HSCTs (hazard ratio (HR) 2.55; 95 % confidence interval (CI) 1.32–4.91; р = 0.03), for post-engraftment BSI – secondary poor graft function (HR 21.70; 95 % CI 7.95–59.24; р <0.0001) and graft failure (HR 21.55; 95 % CI 6.27–74.08; р <0.0001), and gut graft-versus-host disease (HR 12.90; 95 % CI 5.77–28.80; р <0.0001). Thirty-day survival after each BSI episode was 90.3 % and was significantly lower in patients with post-engraftment BSI compared to pre-engraftment (71.9 % vs. 97.5 %; р <0.0001).Conclusion. Gram-negative bacteria prevailed in the etiology of BSI. The main risk factors for pre-engraftment BSI was allo-HSCT from mismatched unrelated donors, for post-engraftment BSI – secondary poor graft function and graft failure. Post-engraftment BSI is associated with worse prognosis.

Highlights

  • Bloodstream infections (BSI) are common after allogeneic hematopoietic stem cell transplantation

  • From January 2018 till May 2021 242 patients after first allo-HSCT were enrolled in the study

  • The majority of transplants were done for acute leukemias (71.9 %) in remission (91.7 %) with reduced-intensity conditioning regimens (71.5 %) and peripheral blood stem cells (74.4 %) as a graft source

Read more

Summary

Materials and methods

From January 2018 till May 2021 242 patients after first allo-HSCT were enrolled in the study. После приживления трансплантата частота ИК выше у больных с реакцией «трансплантат против хозяина» (РТПХ), органной недостаточностью или при наличии вторичной нейтропении [5, 9]. Критериями вторичной несостоятельности трансплантата являлись снижение показателей периферической крови (уровни нейтрофилов

Индукция ремиссии Induction therapy
Профилактика фторхинолонами Fluoroquinolone prophylaxis
Acinetobacter ursingii
Фактор риска Risk factor
Findings
Haploidentical donor
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call